Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study / C. Corti, S.M. Tolaney. - In: ESMO OPEN. - ISSN 2059-7029. - 10:11(2025 Nov), pp. 105861.1-105861.2. [10.1016/j.esmoop.2025.105861]
Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C. CortiPrimo
;
2025
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Corti_response_letter_editor.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
184.17 kB
Formato
Adobe PDF
|
184.17 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
